| Name | Cvs Pharmacy #00374 |
|---|---|
| Organization Name | Cvs State Capital Llc |
| Location | 449 Forest Ave, Portland, Maine 04101 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (207) 772-1928 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke University Comprehensive Cancer Center.
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report reveals.
Researchers from Allegheny General Hospital's (AGH) Department of Orthopaedic Surgery and Center for Genomic Sciences have launched dual groundbreaking studies that may help determine the cause of two common, hard-to-treat problems experienced by patients who undergo orthopedic surgery: a joint replacement that becomes infected and a bone fracture that will not heal properly.
› Verified 3 days ago
| NPI Number | 1134223050 |
| Organization Name | CVS STATE CAPITAL LLC |
| Doing Business As | CVS PHARMACY 00374 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 449 Forest Ave, Portland, ME 04101 |
| Phone Number | 207-772-1928 |
News Archive
Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke University Comprehensive Cancer Center.
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report reveals.
Researchers from Allegheny General Hospital's (AGH) Department of Orthopaedic Surgery and Center for Genomic Sciences have launched dual groundbreaking studies that may help determine the cause of two common, hard-to-treat problems experienced by patients who undergo orthopedic surgery: a joint replacement that becomes infected and a bone fracture that will not heal properly.
› Verified 3 days ago
News Archive
Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke University Comprehensive Cancer Center.
Onyx Pharmaceuticals, Inc. today announced results from a Bayer HealthCare Pharmaceuticals Phase 3 trial evaluating the investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
Survival rates for cancer are continuing to rise even though the number of cases being diagnosed is increasing, an all-Ireland report reveals.
Researchers from Allegheny General Hospital's (AGH) Department of Orthopaedic Surgery and Center for Genomic Sciences have launched dual groundbreaking studies that may help determine the cause of two common, hard-to-treat problems experienced by patients who undergo orthopedic surgery: a joint replacement that becomes infected and a bone fracture that will not heal properly.
› Verified 3 days ago
A Special Place Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1189 Congress St, Portland, Maine 04102 Phone: (207) 775-4048 | |
Atlantic Procare Type: DME Supplier - Customized Equipment Location: 1274 Congress St, Portland, Maine 04102 Phone: (207) 774-1002 | |
Black Bear Medical Inc Type: DME Supplier - Customized Equipment Location: 275 Marginal Way, Portland, Maine 04101 Phone: (207) 871-0008 | |
Community Surgical Supply Of Toms R Type: Durable Medical Equipment & Medical Supplies Supplier Location: 400 Riverside Street, Portland, Maine 04103 Phone: (207) 558-6448 | |
Cvs Pharmacy #00329 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 111 Auburn St, Portland, Maine 04103 Phone: (207) 797-3393 |